Acute Porphyria Drug Database

Monograph

N05AB06 - Trifluoperazine
Propably not porphyrinogenic
PNP

Rationale
Substrate and in some cases inhibitor of Cyp2D6. No basis for assumption of Cyp TDI properties. 40 reports of safe use indcates that the phenothiaze -N/-S heterocycle is devod of porphyrogenicity in a way not significantly influenced by side chain structures.
Chemical description
Phenothiazin derivatives with dimethylaminopropyl side chain or piperazine ring side chain. Generally administered as water-soluble salts.
Therapeutic characteristics
Neuroleptics, anxtiolytics Antimuscarinic effects. Confounding side effects: Tachycardia
Hepatic exposure
In some cases probably significant
Metabolism and pharmacokinetics
Generally metabolized by Cyp2D6, some being inhibitors of CypD6 without effects connected with significant Cyp TDI.
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria. 40 reports of safe use of drugs within these two groups of phenotiazines, none of porphyrogenicity
Similar drugs
Explore alternative drugs in similar therapeutic classes N05A / N05AB or go back.
Tradenames
This list comprises raw data collected from different countries. In some cases, a more comprehensive list of available drug packages is included. Consequently, very similar terms may therefore appear multiple times. Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.


Modalina Stelazine · Stelazine Forte · Terrazine · Trifluoperazine
 
© NAPOS 2025
An unhandled error has occurred. Reload 🗙